GcMAF, the most powerful of the immunotherapies, is the best treatment yet found for cancer. In our clinics 77% of terminal stage 4 cancer patients receive an average 25% tumour reduction in a week, and instead of dying, we send them home recovering.
GcMAF is a human protein and a human right. It has no side effects. It is the lowest risk strategy you can adopt.
It successfully treats 50 other diseases including kidney, hepatitis B and C, autism and cirrhosis of the liver.
Our company and its four scientists have supplied over 11,000 people around the world with GcMAF, including 350 doctors and clinics, and written 33 scientific research papers, peer reviewed and published in the world’s top scientific journals.
300 scientists have written 150 research papers on GcMAF. Just two are linked below.
The first is by five of Japan’s top cancer research institutes, including the prestigious Atomic Bomb Institute of Biomedical Sciences, Nagasaki, who are world leaders in cancer research. On page four you can see the picture of the tumours before treatment, and below them, tumours shrunk 90% in three weeks by GcMAF.
The second paper, published in the most senior of cancer scientific journals, the Journal of Anticancer Research, is written by us. It shows before and after scans of patient’s tumours shrunk by 25% in a week. The fact GcMAF works cannot be disputed.
We put each production batch through 9 tests. Two sterility, one external and independent. Our sterility has always been perfect, and we have supplied 11,000 people with that perfect sterility. We also put it through three activity tests.
In the 8th test we put human breast cancer cells in a petri dish, and add human immune system macrophages. Nothing happens.
Then we add the latest batch of GcMAF. In three days the cancer cells have been eaten by the macrophages.
We have that videoed with time lapse photography.
The 9th test is the same, without the macrophages, so the cancer cannot be eaten. The GcMAF, on its own, then turns the cancer cells back into healthy cells.
We charge €450 for 8 average treatments of GcMAF, as opposed to about €60,000 for a round of chemotherapy.
We have patients who were terminal stage 4, who are now cancer free, who you can talk to.
In our clinics we have 100% success taking pancreatic cancer patients with one or two weeks to live, and three months later they have no symptoms of the disease.
In our laboratory over those 6 years we have developed four versions of our products, and are the only people in the world to have patents on GcMAF molecules.